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Abstract
Performance anxiety consists qf several symptoms experienced in the context qf public
performance and is classified in DSM-III-R under social phobia. Performance anxiety must be
distinguished from panic disorder, generalized social phobia, and generalized anxiety disorder.
Petformance anxiety symptoms can be detrimental to both petformer and performance. These
symptoms can be controlled by the j udicious use ofbeta-adrenergic blocking agents. The use qf
beta-adrenergic blocking agents should be considered as part ofa psychiatric stress-management
programJor these patients.
The ph en omenon of pe rformance a nxiety (or "s tage fri ght ") has been a pprec i-
a ted for man y years . The sym pto ms a re not ed immed iat ely prior to a nd du ri ng
va rious performance tasks , e.g., music, public speaking, a thletics, and test tak ing,
a nd a re referabl e to th e sympathetic nervous syste m. Althou gh no standard series of
sym ptoms spec ific to this cond ition has been develop ed , tachyca rd ia / palpita t ions,
tremor, a nd swea t ing a re cite d most commonly, with various other sym pto ms list ed
less cons iste n t ly (1- 16, T abl e I) .
A small, manageable a mo unt of a u to no m ic arousal may well be adapt ive by
se rving to incr ease th e performer's ene rgy . For many other performers , however ,
th ese symptoms are excessive a nd coun terprod uct ive. Wit ness the viol in ist or arch er
with excessive tremor, th e trumpet er with dry mouth and short ness of br eath , or th e
ac to r with excessive swea ting. This paper will examine th e evalua t ion and ma nage-
ment of performance a nxie ty sym ptoms.
DESCRIPTION AND DIFFERENfIAL DIAGNOSIS
Performan ce anxiety is classifi ed in DSM-III-R as soc ia l ph obia (300 .23) ( 17).
These crite r ia include: a persist ent fear of situa tions in wh ich th e person is expose d to
scru t iny by othe rs, a nd fears th at he / sh e may act in a humilia t ing or e mba rrass ing
manner; expos ure to th e st im ulus provokes a n anxie ty response; th e phobic sit ua t ion
is avo ide d or end ure d with grea t a nxie ty; a nd th e avo idant be havior interferes with
occupa t iona l functioning. DSM-III-R distingui sh es bet ween thos e person s with
"gene ra lized" socia l phobia from those with "d iscre te" soc ia l ph ob ia whic h is limit ed
to performance situations by th e cavea t that th e ge ne ralized type desc rib es those
persons for whom th e phobia situation includes most soc ia l situa t ions. A study by
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H eimberg, Hope, Dodge, and Becker ( 18) compared a group of ge ne ra lized social
ph obics to a group who were ph obic for public speaking only. They found the
ge ne ra lized social ph obics to be lower-functi oning, a nd to have more severe phobic
sym ptoms th an the public speaking phobics. The public speaking phobi cs wer e fou nd
to hav e a noticeabl y gr eater incr ease in heart rate in response to a performance
challe nge , as well as ove re st ima ting th e visibi lity of the ir anxiety symptoms a nd
unde res timating th e qu ality of thei r performan ce whil e bein g observed.
Turner a nd Beid el ( 19) studie d a population of socially anxious person s who
were as ked to give a speech. They found a sign ificant increase in blood pr essure
du ring th e pe r formance task for a subgroup described with " high physiologica l
react ivity." Their study did no t use DSM-III cri teria for social phobia, and th e specific
symptoms of performance a nxie ty vs. ge ne ra lized socia l ph obia were not addressed.
An important distincti on m ust be mad e bet ween social phobia a nd pani c
disorder. Although th e physical a nd cog nit ive sympto ms of the two condit ions show
conside ra ble overlap, th e panic disorder pat ient experiences symptom attacks as
unexp ect ed and not tri ggered by situa t ions in whi ch th e person is the focus of
a tten t ion by others (17) . When th e pani c disorder pat ien t develops phobic avoidance
of socia l situa t ions, it is a fter th e onse t of panic d isord er and du e to fear of having a
panic a ttack (ofte n in a non social situa tio n) , while the socia l phobic is a fra id of ac t ing
in an em ba rrassing or humiliating way (20). The dist inct ion between socia l ph obia
and pa nic disord er has both diagn ostic and the ra peutic importance, as treatment
with tri cyclic a n t ide pressants is recom mended for pan ic disorder, but is gen erally
ine ffec tive for socia l ph obi a (2 1). T o illus t ra te th is poin t , Pohl , Balon and Yeragani
(22) rep orted a case of a mu sician who first developed pan ic a ttacks in a variet y of
situa t ions . Eventua lly, th e sym ptoms of palpitation s, swea ting, chest tightness,
trembling, feelings of panic and fears of "going crazy" occurred only with musical
perform ance. He res ponde d bri efly to prop ran olol, but eventua lly was su ccessfull y
treate d with imprimine. Becau se his init ial sym ptoms were spontaneous, thi s patien t
is mo re acc ura te ly describ ed as having panic disord er ra ther than socia l phobia.
It is pos tula te d th a t patients with socia l ph ob ia limited to performance situa -
tions a re unu su all y responsive to th e peripheral somatic cues that result from
ad re nergic ac tivation (2 1). There is some evide nce that such patients show a mor e
dra m at ic ca rdiovascula r response to stressful performance st imuli ( 18). The patient
noti ces th e somatic sympto ms (which nearly uniformly include tachyca rd ia, sweating,
a nd trem or) and th en develops a cog nit ive percept th at others will be particul arl y
perceptive of th ese somatic symptoms (18,21). This results in a vicious cycle wherein
the somatic sym ptoms lead to th e hypersensitive cog nit ions, lead ing to gr ea ter
pe ripheral symptoms in a positive fee dback loop . This prop osed mechanism is in
contrast to th e centrally driven mech anism felt to be responsible for pani c disorder.
Leib owitz, Gorman , Fyer and Klein not ed th at DSM-III social phobia patients had a
subs ta n t ia lly lowe r incid en ce of lact a te-indu ced pa nic symptoms th an did patient s
suffe ring fro m panic disorder with agorapho bia, further supporting a neuroch emi cal
differen ce between th ese two conditions (2 1).
Social phobia mu st a lso be disti ngui sh ed fro m avoidan t personality disorder,
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whi ch represents a more lon g-standing pattern of soc ia l avo idance with less likeli-
hood of dis cr e te episode s of ph ysical sympto ms . Patients wit h socia l ph obi a a re a lso
prone to a ffec tive illn ess and subst ance abuse , whi ch may be attempts to manage
a nxie ty sympt oms (17). Agras (15) noted a significan t incid ence of com ple te avoid-
a nce of th e phobic situa t ion, occupational cha nge, ami a nt icipa tory lise of alcohol in
patients with public spe a king or mu sical performance forms of soc ia l phobia.
PERFORMANCE ANXIETY IN PERFORIvIER GRO UPS
The frequ en cy of intrusive performan ce anxiet y even a mo ng seasoned perform-
ers is surprising ly high. Performan ce a nxiety does not necessa r ily decr ease with
eit he r increasin g musical pr oficien cy or perfor mance ex pe rience . Among well-known
performers, Arthur Ruben st ein , Pablo Casals, an d Carly Simon a re said to have
suffere d from significan t performance anx ie ty (23). W esn er, Noyes , and Davis ( 10),
in a survey of universit y music students a nd faculty, found th a t 16% of the respon-
dents felt th at th eir performance was markedl y impaired by their anx iety symptom s,
with poor conce nt ra tion, rapid hea rtbeat , t re mo r, sweating and dry mouth th e mo st
com mo nly rep orted performan ce anxie ty sym pto ms. Audit ion s a nd solo perfor-
mances (whe re in th e player is th e mo st exposed to the list ener 's scrutiny) were ci te d
as being "quite a bit" or "ext re me ly" anxiet y pr ovoking by a majority of th e
respondents. The a u tho rs also asked abou t other anxie ty symptoms including panic
a ttacks a nd reported th at 27% a nd 34% of th ei r sa mple claimed to be " ne rvous
pe rso ns" a nd to have had panic a ttacks, resp ectively. Of so me note is th at th eir
qu esti onnaire did not defin e th ese terms fur ther. The st udy showed very little use of
alcohol or drugs of abuse, while 4% of th e " im paired " gro up ad mitted to the use of
pr escription medications to cont ro l performan ce a nx ie ty sym ptoms; beta-blocking
agen ts were not specifica lly qu estion ed for. Thou gh specific psychological psychother-
a pe u tic techniques were not det ailed , ove r 50% of the responde nts repor ted th eir use
for th e management of performan ce a nx iety.
Fishbein and Middlestadt (24) com ple te d a major survey of over 2,000 profes-
sional musicians and found that 24% of th e respondents report ed "s ta ge fright " as a
significa n t medi cal pr obl em; it was (a long with eye strain) th ei r most rep ort ed
medi cal com plain t. However, th e au thors did not define " stage frig ht" in terms of
dis cret e ph ysical and psych ological sym pto ms . They also not ed "acu te anxiet y" as
being reported as a medi cal problem by 13% of th ei r respondent s. Perha ps some of
this latter gro up had panic di sorder sym ptoms not temporally-connected to perfor-
man ce. Other psych ologic sym pto ms cited by the respondents were depression in
17%, slee p disturban ces in 14%, a nd conce rn ove r alcohol consum ption in 20%.
Twenty-seven percent of th e respondents had used bet a-adren ergic block ing age nts
(70% of th ese were " non-pre scr ibed occasional " us ers). O ccasion al use of beta-
blockers was most fr equent before auditions, solo recit als, or difficul t orchestrat al
performances. The vas t majority of those mu sicians wh o used beta-blockers on such
a n occasiona l basis reported success in stage fri ght sym ptom cont rol. Twenty-five
percent of th e stage fr igh t suffere rs had resor te d to psychological counseling (tec h-
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nique un sp ecified ) for sym pto m re lie f, wit h 60% re po r ti ng succ ess. It has been
cla im ed th at conflicts ove r ca ree r cho ice and domesti c tu rmoil may be somewhat
resp on sible for the expe r ie nce of performance anxie ty in the m usicia n (25) .
Va rious a thle t ic eve n ts which require fine motor co ntro l can be adversely
a ffected by the ph ysical symptoms of perform ance a nxie ty. For example, the rifl e
shooter or a rc he r ca n be rendered un st ead y by palpitat ion s or tremor. The bowler,
billiards player, or go lfer will be ill-served by ei ther sweaty pal ms or hand tremor. At a
m ore cog nit ive level , focu sing on othe rs' abili ty to see the signs of performance
a nx ie ty ca n serve to di st ract the com pe t ito r a nd keep him from concentrating on his
a thle t ic skill (26).
Actors a nd public speake rs can be affec te d by performance anxiety symptoms as
well. It is diffi cult to m aintain concen t ra t ion on one 's speaking performance in th e
face of palpita ti on s, sweat ing, tremor or the othe r symp to ms of performance anxiet y.
Also troublesome to the speake r a re dry mouth, vocal t remor, and shortness of
breath.
BETA-ADRE NERGIC BLOCKING AGENTS-RATI O NALE FO R T REATMENT
Beta-adrenergic blo cking agen ts a re thought to ac t per ipherall y to block th e
somat ic com po ne n ts of the anxiet y sta te . These symptoms includ e tachycardia /
palpi tation s, tremor, and swea t ing, as well as vario us other symptoms (Table I). By
block ade of the peripheral manifest a ti on s of a nx iety, th e pa ti en t perce ives les s
a nxie ty, thus blunting the positive feedback loop where in the pe rception of somatic
a nxie ty sym pto ms lead s to a nxious thou ghts whi ch leads to more somat ic symptoms.
It has lon g been a pprecia te d that sym pathe t ic ne rvou s system di sch a rge is associated
with suc h sym p to ms ; beta- adren ergic blockad e is thus a t rea tm ent consist ent with
ph ysiol ogy.
It has ge ne rally been shown that the ac tio n of beta-block e rs in reduci ng anxiet y
sym pto ms is based on th eir peripheral ac t ions; beta-bl ock in g agents kn ow n not to
pen etrat e the blood-brain barrier may reduce a nxie ty sym pto ms, a nd a nx iolysis has
been noted with beta-block er do ses too low to ac hieve ce nt ral ph ysiologica l effects
(27) . Furthermore, in a nxie ty sta tes, th e ac tion of beta-block e rs on peripheral
m anifestation s are more clearly reduced th an a re th e purely psychic m anifesta t ions,
and vari ou s performance ac ts a re improved with just th e peripheral actions of
beta-block ers (11 ,13) .
A study by Mills, Dimsdal e, Ziegler et a l. (28) found lymphocyt e beta-adren ergic
receptor density a nd sensitivity to corre la te with the ca rdiovascu la r response to a
m en tal s t ressor. This is of interest in that excess cardiovascular reactivity may
predict the later d evelopment of ca rdi ovascula r di seas e; it is plausible that excess
card iovascu lar reactivity may cor re la te wit h the degree of performance anxiet y
sym pto ms as well.
Fo st er, Evans a nd H ardcastle (29) moni tored th e pu lse rates of surgeons whil e
they performed op erations a nd while they a tte nde d outpatien t clinics . A typical
increase in pulse to a m ean of 121 BPM was seen in th e surgeo ns while they were
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TABLE 1.
Signs /Symptoms of Performance Anxiety (1-16)
Neuropsychiatric
TREMOR
nervousness
fea r
increased ta lking
rest less ness
decr eased concentration
incr eased mu scle ten sion
"deta ched" feeling
tin gling
Cardiovascu lar
TACHYCARDI A/ PALPITATI O NS
hypert ension
Respi rat ory
Shor tness of Breath
Gas trointest ina l
Nausea
Diar rhea
Derma tologic
SWEAT ING
flush ed skin/ blushing
Other
Dry Mout h
Voice Ch ange
Urgency to Mictu rit ion
operating; 40 mg of oxpre no lol red uced th e during surgery pu lse of th e surgeons to a
mea n of 84 BPM.
C hro nic ad minist ration of beta-adren ergic blocking ag ents is associat ed with a n
incr eas e in th e number of bet a-adren ergic receptor s; thus abrupt d iscontinuation of
th ese age n ts ca n ca use a withdrawal synd ro me. The withdrawal symptoms may
include a nx ie ty, tremulou sn ess, sweat ing an d tachyca rd ia (16) . The notable sim ilar-
ity between th ese sym pto ms a nd t he sym ptoms of performance anx iet y mak e th e
" pe riphe ral so matic cues" mod el of performan ce a nx iety a nd it s man agement by
bet a-adren ergic blockade all t he more plau sibl e .
STUDIES OF BETA-ADRENERGIC BLOCKADE FO R PERFO RMANCE ANXI ETY
AND/OR SOCIAL PH OBIA (TA BLE 2)
Hartley, U ngape n, Davie a nd Spe nce r ( I) studied public speakers who received
eithe r 40 mg propranolol or placebo sixty to nin ety minut es prior to giving a speech.
In part of th eir study, " a nxious" group was se lected on the bas is of th eir high scores
on a sca le of trait a nxie ty . Following th e sp eech, th e subj ects complet ed a scal e ofstate
a nxie ty. Propranolol was associa ted with a sign ificant decrease in th e state a nxie ty
TABLE 2.
Studies of Beta-Adrenergic Blocking Agent s for Symptoms of Performance Anxiety/Social Phobia
00
Medica- Perform ance
Authors: tions : Design : T ask: Result s: Comments:
Hart ley, Unga pen, Propranolol Doub le Blind Pub lic Spea king Propr an olol decreased an xiet y Propr an olol delayed recall
Davie, et a l. ( I) 40 mg Cross-over symptoms in nonverbal behav- of item s in some subjects,
Placebo Con- ior of anxious subjects and de- raising qu estion of a cen-
trolled creased pulse rat e in all sub- tr al action .
j ect s.
j ames, Pear son , Oxpr enolol Doub le Blind Mu sic (Ins tru- Oxprenolol decreased pul se, sys- Oxprenolol had no effect on
Griffith, New- 40 mg Cross-ove r ment al-st rings) tolic BP, tr emor, self-ra tings of mem ory, and had more
bury (2) Placebo Con- nervousness, and improved mu- effect on first day of
tr olled sic performance scores . Ca lm- tr eatment.
ing effect a tt ributed to oxpr e-
nolol.
j am es, Savage (3) Nadolol Doubl e Blind Mu sic (lns tru - Nado lol decreased skin flushin g, Nado lol was chose n for it s
40 mg Cross-over me nta l-str ings) se lf-ra t ing of trembling, pul se hydroph ilicit y.
Diazepam Placebo Co n- rate, and improved bowing '-t"l
2 mg trolled techn iqu e, int onati on , and "Tl
"Tl
overa ll mu sical performan ce. t"l;l:I
Brant igan, Branti- Propr an olol Doubl e Blind Music (Ins tru- Propr an olol decreased pulse T erbutalin e worsen ed per- (/)0
gan, joseph (4) 40 mg Cross-over men tal) and improved self-ra tings form ance anxiety symp- Z
T erbuta line Placebo Co n- sympto ms, mus ical perfo r- '-toms. 0
tr olled mance, and saliva volum e. c
Nefte l, Adler , Atenolol Double Blind Mu sic (ln stru- Atenolol decreased pulse and self- Atenolol was chose n for its ~Kappeli, et al. 100 mg Placebo Con- men ta l-str ings) ra tin gs of perfo rm an ce anxi ety hydrophilicit y. Placebo r-
(30) t rolled sympt om s during performance gro up showed increased 0
"Tl
only; ate nolol improved some pu lse beginning 90 sec-
-e
techni cal aspec ts of perfor- ond s befor e performance (/)
-<
mance. that last ed throughout o:t
performa nce. s
;J
-<
\>'
TABLE 2. ~
Continued C'Jt"'l
a::
Medica- Performance t"'l
Authors: tions: Design : Task: Results: Comme nts: ~
0
Gat es, Saegert, Nadolol Doubl e Blind Mu sic (Singi ng) Nado lol decreased intra-perfor - Man y subjects describ ed 'Tl
-e
Wilson , et al. 20,40,80 Placebo Con- man ce pul se rat e at all doses. decreased "e ne rgy" at t"'l~(5) mg tr olled 20 mg dose-improved perfor- high er doses. Sma ll num- .."0
ma nce by se lf-rating andjudg- ber of subjects prevented ~
es' rat ings. 40 mg, 80 mg authors fro m concluding ~doses- worsen ed perform an ce clear ben efit of lower o
by self-ra t ing and judges' rat- dose. t"'l
ings. ~
Liden, Go t tfries Alpre nolol Doubl e Blind Music (Instr u- Alpr enolol decreased pu lse rat e, Subjec ts were se lf-selecte d ><
(6) 50, 100 Cross-over me nta l) tremor, and blocked increase in for performance anxi et y M
mg Placebo Con- mu scle tone. symptoms. ~
tr olled :§
J am es, Buygoyne, Pind olol Doubl e Blind Mu sic (In str u- Pind olol decreased anxiety, pulse, Pind olol had no effect on ...,:I:
Savage (3 1) 5 mg Placebo Con - menta l) blood press ure increase, and pea k Aows. ee
tro lled improved subjective eva lua tion t"'l~of performance. >Brewer (32) Prop ranolol Placebo Co n- Un ivers ity Exami- Prop ranolol "suggest ive" of irn- Propranolol doses wer e ad- O
10-80 mg trolled nations proved performance in " high j usted to achieve res ting ~t"'l
test anx iety" subje cts . pul se rat e of 55-65 BPM. ~
Taggart , Carru- Oxprenolol Double Blind Public Speaking Oxpreno lol blocked tachycardia 7 patien ts in oxprenolol ~C'J
th ers , Som er- 40 mg Cross-over and EKG abnorma lities, re- group had known coro- 1'5
ville (13) Placebo-Con- lieved anxi ety sympto ms. nary artery disease. ee
trolled r0
Dr ew, Barnes, Propran olol Doub le Blind Verbal Reasonin g Propranolol associa ted with irn- Stude nts reporting anxiety o
Evan s (33) 120 mg Cross-over Men ta l Arith- proved performance. symptoms wer e helped ~~Placebo-Con- meti c most. Side effects re- rJ)
tr olled port ed in nearl y half of
subjects on pro pr an olol.
<;;
TABLE 2.
Continued
""o
Authors:
Siiton en ,Janne
(34)
Liebowitz, Gor-
man, Fyer, et a!'
( I I, 14)
Gorman , Liebow-
itz, Fyer , et a!'
(12)
Medica-
t ions:
Oxpreno lol
40 mg
Atenolol
50, 100
mg /day
Phenelzine
15- 90
mg/day
Atenolol
50,100
mg/day
Design :
Doub le Blind
Cross-over
Placebo-Con-
trolled
Doub le Blind
Placebo Con -
trolled
Op en
No Placebo
Performance
Task:
Bowling
None
None
Results:
Oxprenolol blocked ta chycardia ,
improved scores in subgroup
with high cardiovascular reac-
tivity.
Phen elzin e decreased sympto ms
of gene ralized social phobia;
ate nolol was no better than pla-
cebo for generalized social pho-
bia, but effect ive for discret e
social phobia .
50% of patients with " marked"
and 40% of patient s with
" moderate" improvem ent in
socia l phobia self-ra t ings.
Co mme nts :
Subjects withou t high ca r-
diovascu lar reactivity had
worse scores wit h oxpre-
nolo!'
" Discre te" social phobia
simila r to performan ce
anxi ety.
50% of pati ent s with social
phobia in study had his-
tory of depression ; 50%
had history of a lcohol
abuse . Performance anxi-
ety pati ent s not distin-
guished fro m those with
ge nera lized socia l phobia .
"-tTl
""l
""l
tTl
::0
rJ1
o
z
'0
c
~
r-
o
""l
"tl
rJ1
-<o
:t
~
::<::
-<
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scores, as well as a decr ease in th e observer ratings for signs of anxie ty. Of not e is the
fact th at th e observe r instrument was a n " anxiousne ss" scal e of one to 20; it
apparently did not add re ss individual ph ysical sym pto ms of a nxi et y. When the
authors com pa re d a gro up of anx ious subj ects (on th e basis of sta te and tra it a nx iety
scales) to a non- anxiou s group, it was found th at pr opran olol significan t ly reduced
th e pul se rat e in both gro ups, whil e observers looking for pau ses, stam me ring,
giggling and tremor not ed less speech-rela te d a nxie ty behavior in th e anxious
subj ec ts following propran olol , but no effect of th e d ru g on th e non-anxious. This
distinction implies a neuroch emical differen ce between th e two gro ups. Some impair-
ment in recall of some it ems by a nxious subj ects seen with pr opra nolol sugges ted a
cen t ra l effect of propranolol.
j ames , Griffith , Pearson a nd Newbury (2) studied st ring m usicians receiving 40
mg oxprenolol vs. placebo. The subj ects played a solo piece befor e an a ud ience and
com plete d rating scales for a nx ie ty before and afte r the perfor ma nce, as well as
assessments of performance. Blood pressure and pul se were mo nitored , a nd expe ri-
enced music raters eva luate d th e performan ce for va rious technical points, one of
whi ch was lack of tremor. When receiving ox pr enolol, th e subjects had lower pulse
and blood pressure, less nervousn ess, and improvement in m usical performan ce. T he
area of greates t improvement with th e drug was with t remor. The subjects were 110/
selec ted for nervou sn ess, and t hos e with a hist ory of nervou s or ment al illness were
excluded. The oxpren olol was not ed to have a grea ter effec t befor e the firs t
performan ce, sugges t ing th at sym pto ms may decr ease wit h t im e. A weakness of th is
study was th at th e a u tho rs did not inq uire as to specific ph ysical sym ptoms experi-
enced by th e subj ect s.
james a nd Savag e (3) com pa re d th e effects of 40 mg nad olol and 2 mg diazep a m
on st r ing musicians in a placebo-con trolled s tudy. Na do lol was chosen for its
hydrophilicit y a nd low likelihood of e NS side effects . Subj ects wit h a h ist ory of
nervous illn ess were excluded. The obse rvers noted th e subjects' specific physical
sig ns (t remo r, swea ting , flush ed skin, talking a nd restl essness) ; the subjects rat ed
th emselves for palpitations, loss of conce n t ra t ion, gas t ro in test inal ups et , t rembling,
detach ed feeling, and fr equen cy of micturition, as well as a self-rating on th e qu ality
of th eir performance. The nadolol gro up was not ed to be pa ler than con t rols. Four of
14 subjects had tremor with placeb o; all of th ese improved a fter nad olol. Nadolol was
associat ed with a lower pulse and improvement in bowin g techniqu e a nd in tona t ion.
No differen ce was found in mood st ates on a self-rat ing sca le wit h ac t ive drug.
Diazepam was associat ed with a minor det erioration in perform an ce.
Brantigan, Brantigan and j oseph (4) stud ied instrumenta l mu sicia ns using
pr opranolol and th e bet a-adren ergic agoni st terbutal ine. The subjects were eva lu-
at ed for overall performance, nervou sn ess, and somatic sym pto ms . T he pro pranolol
group showed a signifi cant decr ea se in heart rat e, a n improvemen t in saliva produc-
tion , a nd improvement in th e se lf-re po r ts of va rious ph ysical sym ptoms of perfor-
mance anxiety. The terbutaline, as pr edi ct ed incr ea sed th e symptoms. The subjects'
sta te (but not trait) anxiet y decreased with propranolol. The resu lts of th e m usic
raters' evalua t ion of subjects' performance in part of their study was significantly
better with propranolol.
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Ne fte l, Ad ler, Kappcli e t aI. (30) studied st r ing players on a tenolol vs. pla cebo
and found th e ac t ive drug to decr ease various stage fri ght symptoms (on a stage -
fright rating scale cons ist ing of two cog nitive qu estion s, two ph ysical questions and
two technical/m usical qu estion s) d uring the performance bu t not imm edia tely before
it. As in othe r studies, the act ive drug blocked the during-perfor ma nce ta chycardia.
Urinary ca techo lamine measurements were cons iste n t with sympathoadrenal act iva-
tion by st ress; th e a te no lol was felt to ac t by peripheral blockade of suc h activation
a nd was associa te d with some improvement in technical performa nce. The main
sym pa the tic ac tiva t ion occur re d 90 seconds before th e begi nning of the performance.
A sho rtcoming of t his st udy was th e rela tive lack of screening for phys ical symptoms.
Gates, Saege rt , Wilson et a I. (5) st udie d singe rs with 20 mg, 40 mg, a nd 80 mg of
nad olol a nd showed a limitation of in traperforman ce hea r t rate with all doses. The
m usic j udges' ra tings for the performances showed a slight preference for perfor-
mance with 20 mg nad olol vs. placeb o, while the high er doses resul ted in performan ce
judged as significan t ly poorer. This corre la te d to th e com me nts by some subjects th at
the high er doses decr eased th eir ene rgy . The au thors d id not report th e effec t of th e
me d ica tion on specific sym ptoms.
Liden and Gottfri es (6) st ud ied instrumental musicians on eithe r 50 mg or 100
mg a lpre no lol vs. placebo a nd fou nd a clear improve ment in severity of se lf-re po rts in
two sym ptom groups; palpitation , incr eased m uscle to ne , and t remor were gro uped
as th e "catecho la m ine synd ro me" while othe r less specific symptoms (e.g., un easi-
ness, irritability, a nd head ache) were gro upe d as "other sym ptoms." No differen ce
was found bet ween th e two do ses of alpreno loI. No assessment of th e qu ality of
m usical perfor mance or obse rve r ratings of signs of anxie ty were reported.
J ames, Burgoyne an d Savage (3 1) used pind olol on ins trumental musicians in a
placebo-controlled study. The subjects' pu lse and blood pr essure were measured
before th e performance . The subjects rated both the ir level of anxie ty and th ei r own
performan ce, and th e performance was eva luate d by a n experie nced professional
musician. The pindolol gro up showed signifi cantly lower pul se an d systolic blood
pressure with th e ac tive drug, a nd a lower a nx iety se lf-rat ing and higher performance
ratings by the ra te r in th e group of " better" players. This study did not sp ecifically
ad dress th e various physica l sym ptoms of performa nce anxiety.
Br ewer (32) st udied th e effect of ox prenolol vs. placebo on a "high anxiet y"
group of universit y stude n ts tak ing exa mi nations . H e started subjects at 10 mg
prop ranolol a nd incr eased doses until the subject's res ting pulse was slowed to 60 :± 5
BPM. He conclude d that th ere was a n improved performan ce on examinations by
th ose who would othe rwise be adverse ly a ffec ted by high levels of anxiety, espec ially
those studen ts with prominent ca rdio vascula r sympto ms .
T aggart , Carru the rs and Some rville ( 13) stud ied the effec ts of 40 mg oxpren olol
on su bjects speaking before an aud ience . EKG mo nitori ng of a group of his subject s
with coronary a r tery disease revealed ST depression whe n t hose subjects spoke. T he
ox pre nolol improved th ese EKG abno r malities a nd blocked the anxiety-associat ed
tachycardia ; th eir study did not add ress th e ot her physica l sym ptoms or mental
symptoms of performan ce a nxie ty.
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Drew, Barnes a nd Evans (33) stu di ed the effec ts of 120 mg propra nolol vs.
placebo on stude n t volun teers performing tests of verbal reasoning a nd men tal
a r ithme tic. The act ive drug group was shown to have im proved sco res in bot h
performan ce tasks. U ndesirable effec ts were seen in nearly ha lf of th e subjects
receiving propranolol; th e mo st fre q ue n t ly report ed sym ptoms were nausea , head -
ac he, a nd weak legs. The maj or benefit of t reat ment was seen in a subgroup who
described th emselves as having anxie ty sym pto ms . As on ly a sin gle do se was used in
this study, it is not possible to de termine whether some of th e cite d side effects were
dose related.
Siitone n a nd Janne (34) stud ied th e effec ts of 40 mg oxpreno lol on bowlers in a
placebo-controlled design. The oxpre no lol pr evented pe rforman ce-r ela ted tachycar-
di a a nd was associa te d with im proved bowling scores in a subgroup of subject s who
had exhibite d a significa n t ly high er heart ra te before, d uring, a nd aft er th e compet i-
tion. This finding is consis te n t wit h th e hypothesis th at persons with subs tant ia l
performan ce anxie ty sym pto ms may have a high er degree of cardiovascu lar reactivity
to performance st res sors than other peopl e.
Gorman, Liebowitz a nd Fyer et al. (12) studied te n subj ects who met the
DSM-III criter ia for soc ia l ph ob ia. The subjects all suffe red from various physical
com pla in ts in soc ia l se tt ings; of th ese sym pto ms , pal pita tion s, sweating, and tremor
were th e most com monly reported. No effor t was mad e to separa te a performan ce
anxie ty subtype from gen eralized social phobia in this study, tho ug h non e of th e te n
had a hist ory of spo n taneous panic a ttacks. Five of the subjects had a hist ory of
depression , a nd five had a history of alcoh ol a buse. Doses ranged from 50 mg to 100
mg a te no lol daily for th e six weeks of th e trial. Ni ne of th e ten patient s in th is open,
un controlled study cited " modera te" or " mar ked" improvemen t in th eir socia l
phobia symptoms. Sp ecific sym ptom improvement and ph ysiological measures were
not addressed .
Liebowit z, Gorman a nd Fyer e t al. (11,14) studi ed 87 patients who met th e
DSM-III cr ite r ia for socia l ph obi a in a ra ndomized placebo-controlled trial of a te nolol
and th e monoamine oxidase inhibitor ph enelzin e. Daily a te no lol dos es were eit he r 50
or 100 mg (m ean, 95 mg) whil e dai ly ph enelzine do ses ra nged fro m 45-90 mg (m ean ,
72 mg). Assessm ents included several a nxie ty and depression inventories , plu s a
soc ia l ph obi a scale, which included 12 di scr et e performance fears . Thei r findings were
that ph en elzin e was more effect ive for ge ne ralized soc ia l ph obia , wh ile atenolol was
helpful for th e discr et e performance-related social phobi a . A di fficulty with this study
is th e lack of cle ar distinctions between th e ge ne ralized versus performan ce-relat ed
social phobia gro ups.
PHARMACOLOGICAL PROPERTIES OF THE BETA-ADRE ERGIC BLOCKING
AGENTS STUDIED
The ph armacolo gic properties of th e beta-adren ergic blocking ag e nts used in th e
pr eviously di scus sed performance anxie ty a nd soc ia l ph obia st udies are summarized
in T abl e 3. The cho ice of a specific bet a-adren ergic blocking agent for the treatment
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of t he phys ica l symptoms of performan ce anxiety depends substant ially on two
ph armacological pr oper ti es: lipid vs. H20 so lubi lity and receptor se lect ivity. At en olol
is a ca rdioselect ive (i.e ., beta-one selective) , hydrophilic agen t (20,27,35,36). As a
result , it s bet a-adren ergic actions a re more specific to th e heart a nd to blocking
tachycardia. Because of it s hydrophilicit y, a teno lol has rela tively poor blood-brain
barrier pen etration a nd thus less risk of th e CNS side effec ts occasionally rep or ted
with more lipophil ic beta-adren ergic blockers suc h as pr op ran olol. T he finding in the
studies cite d (12,30) that at eno lol ha s some succes s in blocking th e sym pt om s of
perfo rmance anxiety supports t he hypothesis that su ch sym pto ms a re medi a ted by a
periphe ra l mechanism .
Propra nolol, by con tras t, is a nonselective a nd lipophilic age n t. T he inciden ce of
CNS sid e effec ts from bet a-adrenergic blockade is report ed to be g rea te r with the
more lipophilic age nts , ye t is still infrequent , es pec ia lly a t clinica lly-accept abl e doses
(35). Based on th e th erap eu t ic effec t of bet a-adren ergic blocking ag ents on esse nt ia l
tremor, it has been recommended that a nonselective agent be used wh en tremor is a
significant target symptom (27,36) .
Of th e other beta-adren ergic blocking age n ts cite d in th e above studi es, only
pindolol (moderately lipophilic and non selective) and nad olol (hyd rophi lic a nd
non selective) a re in common use in th e U.S. As a ll of th e mention ed bet a-ad renergic
blocking agen ts cite d showed at least so me effec t in symptomatic cont ro l of perfor-
mance anxiet y, and no psychiatric sid e effec ts were reported in th e stu d ies , it wou ld
TABLE 3.
Pharmacological Properties of Beta-Adrenergic Blocking Agen ts Used in Performance
Anxiety and Social Phobia Studies: (32, 33,37-40)
Relative
Bet a-Blocker: Lipophi licity: Cardioselectivity: Pot en cy: Effecti veness:
( - ) 0.3-1 .0
(- ) 6.0
(- ) 1.0
Propra nolol
(4 studies)
Oxpren olol
(3 studies)
Alprenolol
( 1 study)
Pindolol
(I study)
Nad olol
(2 studies)
At enolol
(3 studies)
high
mod erat e
moderat e
moderate
low
low
(- )
(- )
(+ )
1.0 Effective in 4 studi es ( I, 4, 32,
34
0.5-1.0 Effecti ve in 2 stud ies (2, 13)
Effect ive in " H igh Ca rdiovas-
cula r React ivity" subgrou p
in I study (33)
Effective in I study (6)
Effective in 1 study (31)
Effecti ve in I stu dy (3)
Effecti ve at 20 mg dose, inef-
fecti ve a t 40 mg, 80 mg dose
in I stud y (5)
1.0 Effect ive in 2 s t ud ies (12, 30)
Effective in " Discre te Socia l
Phobia" Subgroup in 1 study
( 11, 14)
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seem appro pr iate to use any of t hem clinica lly. If t remor shou ld not be cont ro lled
with a te no lol, a change to a non selecti ve agent may be tried. Shou ld th e pati ent have
a history of CNS side effec ts from a lipophilic beta-adren ergic blocker, a switch to a
less lipophilic ag ent could be cons ide re d .
OTHER PHARMACOLOGIC AND NON PHARMACO LOG IC TREATMENTS OF
PERFORMANCE ANXIETY
When performan ce a nxie ty is pr esent with t he ge ne ralize d type of social phobia,
ph armacologic treatment with th e monoamine oxidase inhibi tor phenelzin e ca n be
cons ide re d (14,20 ,21 ,37). Doses to conside r range between 45 an d 90 mg daily. The
usual cau t ions apply regarding com plia nce with a tyramine-free d iet and awareness
of possibl e tyr amine reaction.
For symptoms of performan ce a nx ie ty, ph armacologic trea tment should include
benzodiaz epines onl y with great ca u tion. The risk of a lcohol ab use in these patients
mak es th e chance of benzodiazepine abuse significan t. If used for thi s purpose ,
benzodiazepines sho uld be shor t half-life agen ts (e .g ., a lprazo lam, lorazepa m) a nd
used primarily on a limited , PRN ba sis.
Because of th e possible confus ion regarding panic di sord er vs. social phobia , it
may be that some pat ients presenting with performan ce-r elat ed a nxiety symptoms
a re in fact suffe re rs of primary panic disorder. If this is a clinica l possibility, the
patient may respond better to tricyclic a n t ide pressan ts (22).
For nonpharmacolo gic management of performan ce a nx ie ty sym ptoms, va rious
int ervent ions have been recommended . Anxiet y man agement training involves expo-
sure to th e phobic situat ions or a simila r situa t ion. An apt example is Toastmaster's
C lub for th ose with public speaking ph obi a ( 15,37). Relaxat ion training can be
com bine d with th e expos ure to th e phobic situat ion. The ex posure th erapy may be
most su ccessful wh en com bine d with cog nitive th erap y, wh erein th e th era pist helps
th e patient to correct incorrect cog nit ions abo u t th e perceived consequences of his
ph ysical sym ptoms, a nd to repl ace negative expec ta t ions wit h more hopeful ones
regarding performance (37) .
Social skills tra ining can be cons ide re d for those patients wit h associa ted socia l
dysfunction. This may require a gro up format a nd may include assis tance in
comm unica t ion and ass ertiveness. This may be particul arly va lua ble for the patient
who meet s th e crite r ia for avoidant personality di sorder ( 15).
Wha tev er approach is taken for patients with th e performan ce a nx iety subtype
of socia l ph obi a , pharmacologic treatment com bine d wi th psych ologic in terven tion
sho uld have as a commo n goal sym pto m reducti on , increased confi dence in good
performan ce, and consolidate d, lon g-lasting improvement (7).
SUMMARY AND RECO MMENDATIO NS
The evalu ation and management of performan ce a nx iety may challenge th e
psych iatris t 's diagnost ic, pharmacologic, medi cal , and psych otherapeu tic skills. The
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patient who presents for help with disabling performa nce anx iety sympto ms, particu-
larly the mu sician, speake r, ac to r, or at hlete, may be fac ing a ca ree r-t hre a te ning
pr obl em. There is little marg in for erro r in perfor mance for those who pursu e th ose
ac tivit ies professionall y.
Careful history taking for th e physical sym pto ms of performa nce-rela ted sympa-
th etic nervous syste m discharge (t achyca rdi a /palpitation s, sweat ing, and tremor
bein g th e most com monly mention ed ), conside ration of a diagnosis of panic disorder
if such symptoms firs t a ppeared spontaneous ly and a re not a lways related to
performance, a nd di fferentiation of lim ited social phobia from th e more global
disorders ge neralized socia l ph obi a an d avoidant personality disorder are essent ial.
The psychi atrist mus t a lso remain vigi la n t for concurrent depression, substa nce
abuse / depende nce, and othe r ph obi as that may be presen t in this population.
O nce having determined th at a pat ient does ind eed suffer from a limited social
ph obi a /performance a nx ie ty, th e clinicia n may cons ide r beta-adren ergic blocker
th erapy. One mu st be mindful of resting br ad ycardia , diabetes mellitus, rea ct ive
airway disease, Raynaud's ph en om en on a nd othe r medi cal conditions which wou ld
mak e bet a-bl ocker th erap y problem atic. When bet a-blocker th era py is to be tried , th e
clinicia n ca n sta r t at a low dose (e.g., proprano lol 20 mg to 40 mg or at enolol 50 mg)
a nd tit rate upward s to cont rol troublesom e sym ptoms (38). The patient should be
taught to check his pul se a nd no t tak e high er doses if t he rest ing pu lse is less th an 60
BPM. Pulse and blood pressu re sho uld be checked on office visits. If th e patient has a
history of CNS side effects from bet a-adren ergic blockade (including th e ophthalmic
prep a rat ions of timolol, levobunolol, a nd be taxolol), th ese agents should be used very
ca ut ious ly.
For patients who face a sympto mat ica lly ph obi c st im ulus on ly on occasion (e.g.,
th e mu sician who has a n occasional difficult a ud ition or per forman ce), th e use of
bet a-adren ergic blockad e on a PRN basis one or two hours pri or to performance may
be ade qua te . For th e limit ed social ph obic who mu st face his ph obic challenge and
perform well daily, daily dosin g of th e me dica tion may be necessary. For th e athlet e
who need s fine motor control (e .g., the arc he r, go lfer, or billiards pla yer ) , the
clinician mu st learn whether th e use of beta-blocke rs would violate th e rules of the
sport's gove rn ing body. Bet a-adren ergic blocking agents are not among substan ces
banned for Ol ympic a thle te s (39).
It may be most effec t ive to combine ph armacotherapy with behavioral th erap y,
cognit ive res t ruc turing and when need ed social skills t ra in ing to ach ieve lasti ng
results for this challe ng ing clinical pr obl em.
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